/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing a drug to treat cancers with the greatest medical need.
5 February 2021
NEW YORK and LONDON - February 5, 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr Thomas Adams, Ph.D. as an executive director. Dr Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company s pre-clinical and clinical drug development programs and associated intellectual property. Dr Thomas H Adams (age: 78) Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside. The Board believes that Dr. Adams executive leadership and the extensive healthcare expertise he has developed makes Dr. Adams ideally qualified to serve as an additional director of the Company.
NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr. Thomas Adams, Ph.D. as an executive director.
Dr. Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company s pre-clinical and clinical drug development programs and associated intellectual property.
Dr. Thomas H. Adams (age: 78)
Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside. The Board believes that Dr. Adams executive leadership and the extensive healthcare expertise he has developed makes Dr. Adams ideally qualified to serve as an additional director of the Company.
Biotech Stock Picks That Delivered Triple-digit Gains - Is There More Room To Run?
NEW YORK CITY (dpa-AFX) - As 2020 draws to a close, it s time to take a look at the top performing healthcare stocks that we profiled this year. Of the 53 stocks to which our premium subscribers have been alerted, 18 stocks have posted triple-digit gains.
What are the catalysts driving these stocks? Is there more room to run? Let s walk you through the details.
1. DermTech Inc. (DMTK)
DermTech, a commercial-stage genomics company in dermatology, was trading around $11, when we alerted our premium subscribers to it on January 19, 2020. The stock touched a high of $27.42 in intraday trading yesterday and that represents a gain of 136% from our published price.